Roxana Mehran,

Search results

• Ticagrelor monotherapy tops DAPT for high-risk PCI patients

  Roxana Mehran,

  29/09/19

  1 item of Media coverage

  Press/Media

• New COMPLETE Data Affirm Benefit of Nonculprit PCI in STEMI Regardless of Timing

  Roxana Mehran,

  28/09/19

  1 item of Media coverage

  Press/Media

• Coronary Stent Patients May Not Need Long-Term Aspirin –...

  Roxana Mehran,

  27/09/19

  1 item of Media coverage

  Press/Media

• Coronary Stent Patients May Not Need Long-Term Aspirin

  Roxana Mehran,

  26/09/19 → 27/09/19

  4 items of Media coverage

  Press/Media

• Ticagrelor Without Aspirin Three Months After Successful PCI and DAPT Reduces Major Bleeding Without Increasing the Risk of Adverse Events

  Roxana Mehran,

  27/09/19

  1 item of Media coverage

  Press/Media

• Ichan School of Medicine: Coronary Stent Patients May Not Need Long-Term Aspirin

  Roxana Mehran,

  27/09/19

  1 item of Media coverage

  Press/Media

• -AstraZeneca - BRILINTA monotherapy in high-bleeding risk patients who underwent PCI had reduced risk of clinically relevant bleeding than with dual antiplatelet therapy

  Roxana Mehran,

  27/09/19

  1 item of Media coverage

  Press/Media

• TWILIGHT Hits Primary Endpoint, Alters Aspirin Post PCI

  Gregg Stone & Roxana Mehran,

  27/09/19

  1 item of Media coverage

  Press/Media

• Ticagrelor monotherapy reduces bleeding while preserving ischemic benefit in high-risk PCI patients

  Roxana Mehran,

  27/09/19

  1 item of Media coverage

  Press/Media

• BRILINTA Monotherapy in High-Bleeding Risk Patients Who Underwent PCI had Reduced Risk of Clinically Relevant Bleeding Than With Dual Antiplatelet Therapy in the TWILIGHT Trial

  Roxana Mehran,

  26/09/19 → 27/09/19

  11 items of Media coverage

  Press/Media

• Coronary Stent Patients May Not Need Long-Term Aspirin – Mount Sinai.

  Roxana Mehran,

  26/09/19

  1 item of Media coverage

  Press/Media

• BRILINTA Monotherapy in High-Bleeding Risk Patients Who Underwent PCI had Reduced Risk of Clinically Relevant Bleeding Than With Dual Antiplatelet Therapy in the TWILIGHT Trial; Secondary endpoint of non-inferiority achieved for the risk of composite of M

  Roxana Mehran,

  26/09/19

  1 item of Media coverage

  Press/Media

• AstraZeneca: BRILINTA Monotherapy in High-Bleeding Risk Patients Who Underwent PCI had Reduced Risk of Clinically Relevant Bleeding Than With Dual Antiplatelet Therapy in the TWILIGHT Trial

  Roxana Mehran,

  26/09/19

  1 item of Media coverage

  Press/Media

• BRILINTA Monotherapy in High-Bleeding Risk Pati

  Roxana Mehran,

  26/09/19

  3 items of Media coverage

  Press/Media

• Brilinta Monotherapy Reduces Clinically Relevant Bleeding Risk Post-PCI in High-Risk Patients

  Roxana Mehran,

  26/09/19

  1 item of Media coverage

  Press/Media

• High-risk heart patients may not require long-term aspirin use after stent placement

  Roxana Mehran,

  26/09/19

  2 items of Media coverage

  Press/Media

• TCT 2019 Day One: TWILIGHT and Onyx ONE Kick Things Off

  Roxana Mehran,

  26/09/19

  1 item of Media coverage

  Press/Media

• Coronary Stent Patients May Not Need Long-Term Aspirin â Mount Sinai

  Roxana Mehran,

  26/09/19

  1 item of Media coverage

  Press/Media

• IDEAL-LM Probes Short DAPT and a Bioabsorbable-Polymer Stent in Left Main Disease

  Roxana Mehran,

  26/09/19

  1 item of Media coverage

  Press/Media

• BRILINTA Monotherapy in High-Bleeding Risk Patients Who Underwent PCI had Reduced Risk of Clinically Relevant Bleeding Than With Dual Antiplatelet The

  Roxana Mehran,

  26/09/19

  1 item of Media coverage

  Press/Media

• TCT19: LBCT TWILIGHT - Ticagrelor Shows Benefit in Patients With High-Bleeding Risk PCI

  Roxana Mehran,

  26/09/19

  1 item of Media coverage

  Press/Media

• TWILIGHT: Ticagrelor Monotherapy Lowers Bleeding Without Increasing Ischemic Events

  Roxana Mehran,

  26/09/19

  1 item of Media coverage

  Press/Media

• Coronary Stent Patients May Not Need Long-Term Aspirin - Mount Sinai; Results from international clinical trial 'TWILIGHT' could change standard of care for high-risk cases

  Roxana Mehran,

  26/09/19

  1 item of Media coverage

  Press/Media

• TWILIGHT: Switching to ticagrelor monotherapy 3 months post-PCI lowers bleeding vs. DAPT

  Roxana Mehran,

  26/09/19

  1 item of Media coverage

  Press/Media

• TCT 2019 Day One: TWILIGHT Kicks Things Off

  Roxana Mehran,

  26/09/19

  1 item of Media coverage

  Press/Media